Kalaris Therapeutics (KLRS) Operating Income (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Operating Income of -$11.8 million for Q1 2026, down 14.28% year-over-year from -$13.8 million in Q1 2025, and down 9.55% quarter-over-quarter from -$10.8 million in Q4 2025.
Kalaris Therapeutics (KLRS) Operating Income (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Operating Income history runs 8 years deep, the most recent figure standing at -$11.8 million for Q1 2026.
- In Q1 2026, Operating Income fell 14.28% year-over-year to -$11.8 million; the TTM figure through Mar 2026 stood at -$47.6 million (up 19.98% YoY), while the FY2025 annual figure was -$46.2 million, up 10.79% from the prior year.
- Operating Income for Q1 2026 stood at -$11.8 million, down from -$10.8 million in the prior quarter.
- The five-year high for Operating Income was -$2.6 million in Q1 2024, with the low at -$62.4 million in Q4 2023.
- The 5-year median for Operating Income is -$37.8 million (2024), against an average of -$28.3 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income soared 94.07% in 2024, then plunged 303.98% in 2025.
- Kalaris Therapeutics' Operating Income stood at -$40.4 million in 2022, then tumbled by 54.34% to -$62.4 million in 2023, then jumped by 88.57% to -$7.1 million in 2024, then tumbled by 51.42% to -$10.8 million in 2025, then fell by 9.55% to -$11.8 million in 2026.
- Business Quant data shows KLRS's Operating Income at -$11.8 million in Q1 2026, -$10.8 million in Q4 2025, and -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Kalaris Therapeutics | 95.90 Mn | 95.90 Mn | - | -12.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.39 Mn |
| Mar 31, 2026 | -11.83 Mn |
| Dec 31, 2025 | -10.80 Mn |
| Sep 30, 2025 | -12.74 Mn |
| Jun 30, 2025 | -12.26 Mn |
| Mar 31, 2025 | -10.35 Mn |
| Dec 31, 2024 | -7.13 Mn |
| Sep 30, 2024 | -37.85 Mn |
| Jun 30, 2024 | -4.19 Mn |
| Mar 31, 2024 | -2.56 Mn |
| Dec 31, 2023 | -62.41 Mn |
| Sep 30, 2023 | -46.96 Mn |
| Jun 30, 2023 | -47.30 Mn |
| Mar 31, 2023 | -43.23 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -42.95 Mn |
| Jun 30, 2022 | -44.62 Mn |
| Mar 31, 2022 | -43.19 Mn |
| Dec 31, 2021 | -55.80 Mn |
| Sep 30, 2021 | -45.50 Mn |